Biotech Values

[DewDiligence]

Re: ATryn

>>"Although long-term anticoagulation treatment decreased the incidence of recurrent events by 80%, it also resulted in a risk of major hemorrhage of 0.8% per year." What do we know about the risk of major hemorrhage in Atryn?<<

ATryn, like plasma-based antithrombin, is not practical as a chronic (prophylactic) treatment. Oral anticoagulants and anti-platelet drugs are better suited to this indication. Hence, ATryn has not been studied as a chronic treatment and there are no plans to do so.

>>Is there scope for off-label use in this population (not having surgery, child-birth, etc)?<<

There is a lot of room for off-label use of ATryn as an acute treatment in such indications as burns—when clinical studies have been completed in those indications. This is why GTCB has stated that the ultimate sales potential of ATryn is in the $500-700M range.